# Nebivolol ANOCA Treatment Randomized Trial

Study · id `cardio:ct-nct06755801` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06755801](<https://clinicaltrials.gov/study/NCT06755801>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06755801

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT06755801. Randomized; quadruple masking; primary purpose treatment. Start 2025-04-01 (anticipated); primary completion 2026-03-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT06755801, source copy `cardio:ctgov-nct06755801-2025-01-01`, retrieved 2026-11-18)
- Planned start: 2025-04-01 (anticipated) (ClinicalTrials.gov record NCT06755801, source copy `cardio:ctgov-nct06755801-2025-01-01`, retrieved 2026-11-18)
- Primary completion: 2026-03-30 (anticipated) (ClinicalTrials.gov record NCT06755801, source copy `cardio:ctgov-nct06755801-2025-01-01`, retrieved 2026-11-18)
- Completion: 2026-09-30 (anticipated) (ClinicalTrials.gov record NCT06755801, source copy `cardio:ctgov-nct06755801-2025-01-01`, retrieved 2026-11-18)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06755801-2025-01-01`, retrieved 2026-11-18)

## The registry's words

- Brief title: Nebivolol ANOCA Treatment Randomized Trial
- Acronym: MOTORS
- Condition: ANOCA - Angina With Non-obstructive Coronary Arteries
- Condition: Coronary Microvascular Dysfunction (CMD)
- Intervention (Drug): Nevibolol
- Intervention (Drug): Placebo
- Lead sponsor: Spanish Society of Cardiology
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)
- Registry lists this organization as the lead sponsor: Spanish Society of Cardiology (`cardio:org-spanish-society-of-cardiology`)

## Provenance

Content hash: 5cbb163e0ac4994e0429f500b50f708b33667b5295c7e48fa1d4f71470f3c6d1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
